Blood thinner choice guided by risk score for heart attack patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial is testing whether a newer type of blood thinner (called a NOAC) can be used safely right after a heart attack or related event, in addition to the standard two antiplatelet medicines. It focuses on patients who have higher risk signs, like elevated D-dimer levels or a higher PARIS risk score, to see if this approach is safe and effective at preventing future heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Had a heart attack or unstable angina in the past week
- Have either a high D-dimer blood test result or a high PARIS risk score
- Have had a stent placed (PCI) and be taking two antiplatelet medicines
- Not have low blood counts, serious bleeding history, stroke, or severe kidney or liver disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways to lower the chances of another heart attack: taking the standard medicine (clopidogrel) versus taking a combination of aspirin and a lower dose of a blood thinner (rivaroxaban). If you join, you'll be assigned to one of these options to see which works better for people like you.
This trial tests whether tailoring anti-platelet (blood clot prevention) treatment can better protect people at higher risk of heart or blood-vessel problems after a drug-eluting stent. It may help prevent future clots and complications, especially in patients with certain high-risk health conditions or complex stent/scar tissue features.
This study compares two blood-thinning medicines to see which works better for people who have both atrial fibrillation (irregular heartbeat) and heart disease. It aims to reduce the risk of heart attack or stroke while avoiding bleeding problems.
This study tests whether taking dabigatran (a blood thinner) combined with ticagrelor (a blood clot preventer) is safe and effective for patients with irregular heart rhythm (atrial fibrillation) who recently had a heart attack and received a stent. The goal is to prevent future blood clots while minimizing bleeding risks.
This trial studies which blood-thinner (antiplatelet) strategy is safest and most effective for people at high risk of bleeding after a procedure called PCI. It also looks at longer-term outcomes and whether adjusting treatment can improve safety without losing heart protection.
This trial studies which blood-thinning medicine combination is safest and most helpful after coronary bypass surgery combined with a procedure to unblock the artery (endarterectomy). It focuses on preventing dangerous blood clots while also avoiding excess bleeding.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.